0001193125-20-251147.txt : 20201023 0001193125-20-251147.hdr.sgml : 20201023 20200922144559 ACCESSION NUMBER: 0001193125-20-251147 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Prelude Therapeutics Inc CENTRAL INDEX KEY: 0001678660 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811384762 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: (302) 547-3768 MAIL ADDRESS: STREET 1: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: Prelude Therapeutics Inc. DATE OF NAME CHANGE: 20160630 CORRESP 1 filename1.htm CORRESP

September 22, 2020

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention:

  

Jeffrey Gabor

 

Laura Crotty

 

Rolf Sundwall

 

Jeanne Baker

 

Re:

Prelude Therapeutics Incorporated

Registration Statement on Form S-1 (File No. 333-248628)

Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advise that as of the date hereof, approximately 3,016 copies of the Preliminary Prospectus dated September 21, 2020 were distributed to prospective underwriters, institutional investors and prospective dealers in connection with the above-captioned Registration Statement.

We wish to advise you that the participating underwriters have informed us that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

We hereby join in the request of the registrant that the effectiveness of the above-captioned Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Time, on September 24, 2020 or as soon thereafter as practicable.

[Signature page follows]

Very truly yours,

MORGAN STANLEY & CO. LLC

GOLDMAN SACHS & CO. LLC

BOFA SECURITIES, INC.

As representatives of the Underwriters

MORGAN STANLEY & CO. LLC

 

By:  

/s/ Chris Rigoli

  Name:   Chris Rigoli
  Title:   Vice President

GOLDMAN SACHS & CO. LLC

 

By:  

/s/ Elizabeth Wood

  Name:   Elizabeth Wood
  Title:   Managing Director, Goldman Sachs Investment Banking Division

BOFA SECURITIES, INC.

 

By:  

/s/ Greg Butz

  Name:   Greg Butz
  Title:   Managing Director

[Signature Page to Prelude Therapeutics Incorporated Acceleration Request]